Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Charged multivesicular body protein 7 (CHMP7)
- Target
- CHMP7
- Molecular classification
- ESCRT-III family (Endosomal sorting complexes required for transport), Membrane-sculpting protein, Other (not a classic receptor, enzyme, or ion channel)
01
Overview
Charged multivesicular body protein 7 (CHMP7) is an ESCRT-III-like protein essential for endosomal sorting, multivesicular body (MVB) assembly, and membrane dynamics in eukaryotic cells[1][2][3][4][5][7]. It possesses both N-terminal and C-terminal SNF7 domains that enable interaction with other ESCRT-III components, such as CHMP4 and LEM2, facilitating membrane bud neck shearing, vesicle release, and nuclear envelope sealing after mitosis[5][7]. CHMP7 is involved in protein degradation, membrane repair, autophagy, and is emerging as a biomarker and therapeutic target in cancer, neurodegeneration, and viral infection research[2][3][7].
- Other names
- Chromatin-modifying protein 7CHMP family, member 7MGC29816
02
Mechanism of action
If targeted, hypothetical mechanisms would involve modulation of ESCRT-III-mediated membrane remodeling, endosomal sorting, or nuclear envelope sealing[3][5][7].
03
Biological functions
Endosomal sorting and multivesicular body (MVB) assemblyNuclear envelope reformation and sealing during mitosisCytokinesis (midbody abscission)Autophagy and membrane repairUbiquitinated protein degradationDNA mismatch repair involvement and cancer stemness regulation
04
Disease associations
Cancer (implicated in various tumor types, poor prognosis linked to low expression)Neurodegenerative diseases (Frontotemporal Dementia and/or Amyotrophic Lateral Sclerosis 7, Spinal Muscular Atrophy)Viral infection (involved in HIV life cycle)
05
Safety considerations
Theoretical safety risks include disruption of critical membrane repair, nuclear envelope dynamics, and endosomal sorting, potentially leading to cell death, impaired cellular division, or neurodegeneration. However, therapeutic targeting remains exploratory.
06
Biomarkers
CHMP7 expression and DNA methylation status are correlated with cancer prognosis and may serve as prognostic biomarkers in multiple tumor types
Beyond the preview
Go deeper on Charged multivesicular body protein 7 (CHMP7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Charged multivesicular body protein 7 (CHMP7).